Texas Attorney General Ken Paxton filed suit against Pfizer's drug distributor Tris Pharma, alleging it exaggerated the efficacy of an attention-deficit/hyperactivity disorder medication to the state's Medicaid program.
Sales representatives for Dyanavel extended-release told physicians the drug worked faster than other ADHD medications and other unproven benefits, according to the lawsuit.
The alleged "false and/or misleading messages regarding the efficacy of Dyanavel XR were disseminated repeatedly on thousands of sales calls to Texas Medicaid providers and decision makers," the lawsuit says.
A second lawsuit accuses Tris of altering quality control results as tests were showing another ADHD drug, Quillivant, failing to dissolve. Despite this, Pfizer allegedly persuaded Texas' Medicaid program to add the medication to its list of preferred drugs.
Pfizer said it plans to dismiss the charges.